Fatal Toxic Intrahepatic Cholestasis Secondary to Glibenclamide

N. Krivoy,Azzam Zaher,Baruch Yaacov,G. Alroy
DOI: https://doi.org/10.2337/diacare.19.4.385
1996-04-01
Diabetes Care
Abstract:quired treatment with oral antibiotics. Another patient complained of two episodes of recurrent pain at the pump sideport, which resolved within 4 months— the first time spontaneously and the second time with rest and pain medication. Fourteen pump-pocket complications occurred during long-term followup. Three episodes of pain at the pump pocket resolved spontaneously or after short treatment with pain medication. In one patient, a small nonpainful subcutaneous nodule formed over the catheter flange and resolved spontaneously. Two pump migrations (one associated with the impairment of skin integrity) occurred, and pumps were explanted. Eight additional events of impaired skin integrity (i.e., redness of the skin with or without tenderness and pain, thinning of the skin, and skin erosion) at the pump pocket were noted, resolving spontaneously (n = 2) or requiring surgical intervention for pump explant (n = 5) or skin graft (n = 1). The overall rate of pump-pocket complications in this long-term trial was 5.3/100 patient-years with a rate of surgical intervention for pump-pocket complications of 1.8/100 patient-years. Of the seven pumps explanted because of pumppocket complications, three were replaced at different sites. No difference in the rate of pump-pocket complication was observed between the intraperitoneal and intravenous route of insulin delivery. The rate of pump-pocket complications we observed is similar to that reported during other clinical trials with implantable insulin pumps (2-6). Therefore, the high rate of pump-pocket complications reported by Renard et al. (1) does not reflect either the experience with other pump models (including our 435 patient-years cumulative experience) or what was observed during the use of the same pump, the Minimed Implantable Pump model 2001, in other trials (4,6). While an estimate of physical activity in all our patients is not available, our patients' jobs and activities cover a broad spectrum, and many of them exercise regularly without an increase in the rate of pump-pocket complications. However, physical activity shortly after pump implantation might interfere with healing and possibly favor pump-pocket infections. The experience of Renard et al. (1) suggests that multiple surgical attempts to correct the pump pocket in the case of skin atrophy or skin erosions or to reposition the device in the case of history of pump-pocket infections have a low rate of success and may account for an increased rate of pump-pocket complications. In our opinion, pump-pocket complications after implantation of pumps for long-term insulin therapy are a rare event. Nevertheless, a careful survey of pump-pocket complications is important in identifying predisposing factors, establishing the need for prophylactic antibiotic therapy (as for other prosthetic devices), and defining guidelines for treatment.
What problem does this paper attempt to address?